Humana upgraded to Neutral at BofA after Trump win

As previously reported, BofA upgraded Humana (HUM) to Neutral from Underperform with a price target of $308, up from $247, on the results of the election. The risk reward at these valuations have “dramatically improved” as the potential for stronger rates, and reduced scrutiny on stars and antitrust, each give Humana “a potential avenue for stock appreciation,” the analyst tells investors. However, given the somewhat binary nature of these catalysts, the firm is maintaining its trough $13 of EPS in 2026 estimates as it awaits more clarity, the analyst added.